MARKET

LIAN

LIAN

Lianbio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.155
-0.045
-2.05%
Opening 14:12 06/29 EDT
OPEN
2.190
PREV CLOSE
2.200
HIGH
2.190
LOW
2.110
VOLUME
95.83K
TURNOVER
153.18K
52 WEEK HIGH
16.37
52 WEEK LOW
2.110
MARKET CAP
233.33M
P/E (TTM)
-1.4007
1D
5D
1M
3M
1Y
5Y
LianBio to Participate in June Investor Events
SHANGHAI, China and PRINCETON, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that members of the manage...
GlobeNewswire · 06/02 20:02
Lyra Therapeutics initiated with an overweight rating at Cantor Fitzgerald; sees 147% upside
Cantor Fitzgerald initiated Lyra Therapeutics (NASDAQ:LYRA) with an overweight rating saying the company's pipeline is not appreciated enough. The firm has a $15 price target (~147% upside based on Monday's
Seekingalpha · 05/24 16:55
BRIEF-LianBio Reports First Quarter 2022 Financial Results And Provides Corporate Update
reuters.com · 05/12 12:31
LianBio GAAP EPS of -$0.26
LianBio press release (NASDAQ:LIAN): Q1 GAAP EPS of -$0.26. Cash, cash equivalents, marketable securities and restricted cash at March 31, 2022 totaled $389.1 million compared to $403.2 million as of December 31,
Seekingalpha · 05/12 12:31
LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update
LianBio’s partner, Bristol Myers Squibb, has received U.S. FDA approval of mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM) Registrational Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients with...
GlobeNewswire · 05/12 12:00
BRIEF-LianBio Completes Phase 1 Pharmacokinetic Study Of Mavacamten In Healthy Chinese Volunteers
reuters.com · 05/09 12:17
LianBio Completes Phase 1 Pharmacokinetic Study of Mavacamten in Healthy Chinese Volunteers
  Mavacamten demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers Study was conducted in parallel with ongoing Phase 3 EXPLORER-CN trial of mavacamten in
Benzinga · 05/09 12:04
Is LianBio (NASDAQ:LIAN) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 05/09 11:41
More
No Data
Learn about the latest financial forecast of LIAN. Analyze the recent business situations of Lianbio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
25.00%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LIAN stock price target is 15.78 with a high estimate of 27.00 and a low estimate of 7.13.
High27.00
Average15.78
Low7.13
Current 2.155
EPS
Actual
Estimate
-0.76-0.57-0.38-0.19
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 37
Institutional Holdings: 85.95M
% Owned: 79.38%
Shares Outstanding: 108.28M
TypeInstitutionsShares
Increased
4
380.49K
New
13
1.57M
Decreased
5
2.02M
Sold Out
12
3.41M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.94%
Pharmaceuticals & Medical Research
+0.95%
Key Executives
Chairman/Executive Director
Konstantin Poukalov
President
Debra Yu
Chief Executive Officer/Director
Yizhe Wang
Chief Financial Officer
Yi Larson
General Manager
Pascal Qian
Other
Brianne Jahn
Director
Neil Kumar
Director
Adam Stone
Independent Director
Wei Wei Chen
Independent Director
Tassos Gianakakos
Independent Director
Susan Silbermann
Independent Director
Jesse Wu
No Data
No Data
About LIAN
Lianbio is a China-based company engaged in the research and development (R&D) and commercialization of innovative drugs. The Company has established production lines for nine candidate products, including Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX13, LYR210, Sisunatovir. The Company's products cover five different treatment areas, including cardiovascular, cancer, ophthalmology, inflammatory diseases and respiratory indications.

Webull offers kinds of LianBio - ADR stock information, including NASDAQ:LIAN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIAN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LIAN stock methods without spending real money on the virtual paper trading platform.